Ticker brief · 2026-08-16
TMDX TRANSMEDICS GROUP INC
Flight acceleration revives bull case while scalability doubts linger
Consumer, Non-cyclical · Healthcare-Products
Lean: bullishlast close
$88.43
1 day
-3.6%
14 days
-0.2%
mkt cap
$2.4B
signals 14d
42
authors 14d
14
crowd 14d
+1.4σ
The tape is bullish, and the strongest recent trader scores favor patient fundamental upside rather than the sparse bear case. The late-week shift was flight activity exceeding 50 in one day and implying nearly 50% YoY growth, strengthening the Q3 acceleration hypothesis. Concentrated equity holdings, LEAP interest, and distant valuation targets make this a long-duration, high-beta trade requiring operating confirmation.
BULL CAMP
Bulls argue accelerating flight activity should lift Q3 service revenue while kidney, Europe, and broader transplant penetration create a multi-year revenue and margin runway. They view the earnings selloff and planned investment cycle as investor impatience rather than business deterioration.
Key voices@JonahLuptonMEDIUM-HIGHA-0.30@nataninvestingMEDIUM-HIGHB-1.17@SuEricGPMEDIUMB+2.07@KabraxFXMEDIUMB+2.15@mathlonningMEDIUMA-0.77
“Daily flights imply nearly 50% YoY growth and support expectations for a very strong Q3.”— @mathlonning · tweet ↗
BEAR / SKEPTIC
Bears question whether the model scales beyond liver transplants and argue valuation already discounts substantial expansion. Near-term technical skeptics also see high volatility, weak support, and a possible downside wave.
Key voices“The moat appears real, but valuation anticipates growth and scalability beyond liver transplants remains uncertain.”— @Unclestocknotes · tweet ↗
Hypotheses10direction · basis · magnitude · supporters — NEW = first seen this week
▲Accelerating flight activity signals market-share gains, sequential Q3 revenue growth, and meaningful upside to current operating expectations.
@mathlonningMEDIUMA-0.776s · insight
▲Kidney approval and adoption can create more than $1B of incremental revenue and materially expand TMDX by 2030–2032.
▲New revenue sources, transplant-market expansion, and improving margins can sustain accelerating growth and a premium medtech valuation through 2029.
@mathlonningMEDIUMA-0.771s · insight@JonahLuptonMEDIUM-HIGHA-0.301s · insight@P_Earns24LOW-MEDIUMC+0.841s
▲Future FDA approval can trigger a recovery because trial delays and the roughly 50% decline are already priced in.
@mathlonningMEDIUMA-0.771s · insight
▲The reversal and bullish triangle structure indicate improving momentum, with measured upside targets extending from $280–300 to $650–660.
@AlphaScout360LOW-MEDIUMC-4.452s@Apollo_21milLOW-MEDIUMB-0.151s · insight@PharmdcaMEDIUM-HIGHC+0.821s@mathlonningMEDIUMA-0.771s · insight
▼High volatility, absent support, and a possible Wave C setup leave TMDX vulnerable to renewed technical downside.
@AlphaScout360LOW-MEDIUMC-4.451s@FintwitAiLOW-MEDIUMC+1.141s
◆TMDX is extremely undervalued, with a one-year $206 target implying 148% upside from prevailing levels.
@nataninvestingMEDIUM-HIGHB-1.171s
▲Planned margin compression reflects deliberate investment rather than deterioration, positioning patient holders for eventual operating leverage.
@SuEricGPMEDIUMB+2.072s · insight
▲Management's reiterated margin guidance, defensible moat, reimbursement progress, and logistics contracts support confidence in execution after the selloff.
@mathlonningMEDIUMA-0.773s · insight
▼TMDX's valuation already anticipates substantial expansion while scalability beyond liver transplants remains insufficiently proven.
@UnclestocknotesMEDIUM-HIGHB-1.971s · insight
News / data points5discrete events + data quoted by authors
@mathlonningMEDIUMA-0.77
A 50-plus-flight day indicates booming activity and potential market-share gains.
@mathlonningMEDIUMA-0.77
More than 30 daily flights versus 22.3 last August imply 35%+ YoY growth.
@mathlonningMEDIUMA-0.77
August activity exceeded 30 daily flights, supporting sequential revenue growth through Q3.
@mathlonningMEDIUMA-0.77
A competitor received European heart-device approval, supporting the sector regulatory backdrop.
@FintwitAiLOW-MEDIUMC+1.14
TMDX sits at the 28th percentile with high volatility and no established support.
Position disclosures3skin in the game
@nataninvestingMEDIUM-HIGHB-1.17
TMDX represented 27.7% of the disclosed portfolio.
@SuEricGPMEDIUMB+2.07
Remains invested following a Q1 2026 thesis review.
@mathlonningMEDIUMA-0.77
Initiated a position after an earnings-driven selloff viewed as an overreaction.
Desk readconvergence assessment
The view is strongly converged around flight-led Q3 improvement and multi-year transplant expansion, with positive contributions from authors carrying trader scores of 5.1, 4.55, and 2.31. The bear camp is smaller and partly lower-credibility, although Unclestocknotes provides a credible scalability challenge; the most prolific bull, mathlonning, has a sharply negative -3.43 trader score, tempering the apparent breadth. Sustained product growth, margin delivery, and kidney or European milestones would confirm the bull case, while service strength without product scalability would validate the bear objection.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 58% mid · 34 pctile own 1y | IV/HV 0.91× |
| Skew — 25Δ RR 30d | +0.129 100 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +1.91 normal | 5-session Δ +1.76 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-06-03 (z=2.3) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now +0.30 (−1 bearish … +1 bullish)
Who spoke14
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @mathlonning | A | -0.77 | 16 | +0.49 |
| @nataninvesting | B | -1.17 | 7 | +0.62 |
| @JonahLupton | A | -0.30 | 3 | +0.72 |
| @ripster47 | C | +0.24 | 3 | +0.58 |
| @Apollo_21mil | B | -0.15 | 3 | +0.15 |
| @JarvisFlow | C | · | 2 | +0.50 |
| @CaesarCapitalz | C | -0.81 | 1 | +0.60 |
| @StockChaser_ | C | -2.36 | 1 | +0.35 |
| @InversorNovato_ | C | +2.10 | 1 | +0.60 |
| @hiddensmallcaps | B | -0.77 | 1 | +0.45 |
| @growthrapidly | C | -1.63 | 1 | +0.78 |
| @ID_Research_ | A | +0.82 | 1 | +0.40 |
| @CKCapitalxx | C | -0.19 | 1 | +0.80 |
| @mmonis | C | -1.14 | 1 | +0.50 |
Recent signals30of 42 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @mathlonning | +0.30 | Sees CHOPS approval as a near-term catalyst and otherwise expects an $85-$95 range. | — | tweet ↗ |
| 2026-08-26 | @mathlonning | +0.55 | Expects September case-volume recovery and says growth remains above 30% | -4.1% | tweet ↗ |
| 2026-08-26 | @mmonis | +0.50 | Calls the displayed TMDX setup promising | -4.1% | tweet ↗ |
| 2026-08-25 | @ripster47 | +0.70 | Says long-term, research-backed conviction is producing large wins in BULL and TMDX. | -5.5% | tweet ↗ |
| 2026-08-25 | @nataninvesting | +0.50 | Discloses long positions in four healthcare names and a thesis that select medtech stocks remain attractively priced. | -5.5% | tweet ↗ |
| 2026-08-25 | @mathlonning | +0.30 | Says TMDX flight data remains promising despite little recent price action. | -5.5% | tweet ↗ |
| 2026-08-24 | @CKCapitalxx | +0.80 | Detailed bullish TMDX thesis covering clinical evidence, reimbursement, logistics moat and long-term targets. | -5.5% | tweet ↗ |
| 2026-08-23 | @nataninvesting | +0.60 | Buy the dip in TMDX. — Explicitly presents a buy-the-dip instruction for TMDX. | -6.7% | tweet ↗ |
| 2026-08-23 | @ID_Research_ | +0.40 | Says TMDX is halfway toward the desired outcome while cautioning that victory is premature. | -6.7% | tweet ↗ |
| 2026-08-23 | @nataninvesting | +0.80 | Discloses a 30% TMDX position and expects continued gains from growth, valuation and medtech rotation. | -6.7% | tweet ↗ |
| 2026-08-22 | @JarvisFlow | +0.50 | Reports TMDX options flow flipping from call-selling resistance at $95 to bullish sweeps. | -6.7% | tweet ↗ |
| 2026-08-22 | @JarvisFlow | +0.50 | Reports TMDX options flow flipping from a $95 call-selling ceiling to bullish sweeps. | -6.7% | tweet ↗ |
| 2026-08-22 | @Apollo_21mil | +0.10 | Updates disclosed holdings and says GOOGL was called away while at least half of SOFI will be called. | -6.7% | tweet ↗ |
| 2026-08-22 | @mathlonning | +0.65 | Projects TMDX Q3 revenue above Q2 with over 35% YoY growth and performance ahead of consensus. | -6.7% | tweet ↗ |
| 2026-08-22 | @nataninvesting | +0.55 | Discloses portfolio weights and performance, led by a 30% TMDX position. | -6.7% | tweet ↗ |
| 2026-08-21 | @nataninvesting | +0.55 | Lists potential fourth-quarter catalysts after two poor quarters. | -6.7% | tweet ↗ |
| 2026-08-21 | @mathlonning | -0.10 | Questions the delay in FDA approval for CHOPS ahead of TMDX earnings. | -6.7% | tweet ↗ |
| 2026-08-21 | @mathlonning | +0.45 | Reports over 30 daily flights in August and 43 in 24 hours, implying another record quarter. | -6.7% | tweet ↗ |
| 2026-08-20 | @mathlonning | +0.75 | Projects Q3 revenue above $190M and roughly 35% growth from strong August performance. | -2.7% | tweet ↗ |
| 2026-08-20 | @mathlonning | +0.55 | Observes that TMDX has appeared positive almost daily for two weeks. | -2.7% | tweet ↗ |
| 2026-08-19 | @growthrapidly | +0.78 | Add TMDX back to the buy list for a future purchase. — Calls TMDX undervalued at $94 and explicitly adds it to a buy list. | -5.9% | tweet ↗ |
| 2026-08-19 | @ripster47 | +0.65 | Portfolio update reiterates prior long-term bullish positions and entry levels across four stocks. | -5.9% | tweet ↗ |
| 2026-08-19 | @nataninvesting | +0.90 | Continuing to add PRCT, TMDX, and META as high-conviction holdings. — Names three top opportunities, gives fair values and five-year returns, and says the author continues adding. | -5.9% | tweet ↗ |
| 2026-08-19 | @hiddensmallcaps | +0.45 | Groups stocks as possible crash-then-rebound candidates, with uncertainty on RBLX and BROS. | -5.9% | tweet ↗ |
| 2026-08-19 | @mathlonning | +0.40 | Expects outperformance if management executes, while warning valuation is no longer cheap. | -5.9% | tweet ↗ |
| 2026-08-19 | @JonahLupton | +0.75 | Discloses fund long and gives a bullish multi-year growth and valuation thesis. | -5.9% | tweet ↗ |
| 2026-08-19 | @mathlonning | +0.70 | Strongly positive declaration that TMDX has recovered. | -5.9% | tweet ↗ |
| 2026-08-19 | @InversorNovato_ | +0.60 | Promotes prior biotech signals after gains of 21%, 138%, and 13.8%. | -5.9% | tweet ↗ |
| 2026-08-19 | @mathlonning | +0.30 | Notes TMDX has rebounded substantially from its lows but remains down YTD. | -5.9% | tweet ↗ |
| 2026-08-19 | @Apollo_21mil | -0.10 | Says the U.S. is far behind while listing healthcare names, with context unclear. | -5.9% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.